Key Points
- COO Kristen Oelschlager sold 14,888 shares on December 17 at an average price of $39.31 for proceeds of $585,247, leaving her with 12,323 shares — a 54.71% reduction in her position.
- Castle Biosciences beat expectations in its latest quarter (EPS -$0.02 vs. -$0.34 expected; revenue $80.55M vs. $71.06M), though the company still reports a negative net margin.
- The stock trades near its 12‑month high (~$40), has a market cap of about $1.15B, is 92.6% institutionally owned, and carries a consensus "Moderate Buy" rating with an average price target of $39.14.
Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek Maetzold sold 509 shares of the business's stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $40.04, for a total transaction of $20,380.36. Following the sale, the insider directly owned 34,360 shares in the company, valued at $1,375,774.40. The trade was a 1.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Castle Biosciences Price Performance
CSTL stock opened at $39.44 on Friday. The company has a fifty day moving average price of $32.81 and a 200-day moving average price of $24.60. The company has a market capitalization of $1.15 billion, a P/E ratio of -87.64 and a beta of 1.14. Castle Biosciences, Inc. has a 52-week low of $14.59 and a 52-week high of $40.61. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.31 and a current ratio of 6.47.
Castle Biosciences (NASDAQ:CSTL - Get Free Report) last issued its quarterly earnings data on Monday, November 3rd. The company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.32. The company had revenue of $80.55 million for the quarter, compared to analysts' expectations of $71.06 million. Castle Biosciences had a negative net margin of 3.56% and a positive return on equity of 1.73%. As a group, equities analysts expect that Castle Biosciences, Inc. will post 0.44 EPS for the current year.
Hedge Funds Weigh In On Castle Biosciences
A number of institutional investors and hedge funds have recently modified their holdings of CSTL. Franklin Resources Inc. grew its position in shares of Castle Biosciences by 0.5% during the 3rd quarter. Franklin Resources Inc. now owns 99,787 shares of the company's stock worth $2,272,000 after buying an additional 540 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Castle Biosciences by 4.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,441 shares of the company's stock worth $309,000 after acquiring an additional 655 shares in the last quarter. Envestnet Asset Management Inc. grew its holdings in Castle Biosciences by 1.0% in the second quarter. Envestnet Asset Management Inc. now owns 70,478 shares of the company's stock worth $1,439,000 after purchasing an additional 707 shares during the period. Inspire Investing LLC increased its stake in Castle Biosciences by 4.0% in the third quarter. Inspire Investing LLC now owns 19,887 shares of the company's stock valued at $453,000 after purchasing an additional 770 shares in the last quarter. Finally, CWM LLC increased its stake in Castle Biosciences by 80.6% in the third quarter. CWM LLC now owns 1,911 shares of the company's stock valued at $44,000 after purchasing an additional 853 shares in the last quarter. 92.60% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
A number of brokerages have recently issued reports on CSTL. Robert W. Baird raised their price objective on Castle Biosciences from $39.00 to $41.00 and gave the stock an "outperform" rating in a research report on Tuesday, November 4th. BTIG Research increased their target price on shares of Castle Biosciences from $38.00 to $50.00 and gave the company a "buy" rating in a research report on Friday, December 12th. Zacks Research upgraded shares of Castle Biosciences from a "hold" rating to a "strong-buy" rating in a research report on Monday, October 20th. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Castle Biosciences in a research note on Monday. Finally, Canaccord Genuity Group reiterated a "buy" rating and set a $37.00 price objective on shares of Castle Biosciences in a research report on Tuesday, September 9th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $39.14.
Check Out Our Latest Report on CSTL
Castle Biosciences Company Profile
(
Get Free Report)
Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company's proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.
The company's flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
